文献速递慢性肾脏病

维立奴雷联合别嘌醇治疗CKD的随机对照试验

Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial.
PubMed 文献 · J Am Soc Nephrol · 2024-02-20

SAPPHIRE试验为2b期随机安慰剂和活性对照研究,纳入861例伴高尿酸血症的CKD患者,比较维立奴雷(3、7.5、12 mg)联合别嘌醇300 mg与单用别嘌醇或安慰剂对白蛋白尿的影响;34周时各治疗组UACR变化无差异,联合治疗未降低白蛋白尿或eGFR下降,但剂量依赖性降低血尿酸。

要点

  • 维立奴雷联合别嘌醇未降低CKD患者34周UACR。
  • 联合治疗未延缓60周eGFR下降。
  • 联合治疗剂量依赖性降低血尿酸。

核心结论

  • 维立奴雷联合别嘌醇未降低UACR或延缓eGFR下降,但较单用别嘌醇或安慰剂进一步降低血尿酸。

研究设计与样本

  • 随机、安慰剂和活性对照的2b期试验,纳入861例血清尿酸≥6.0 mg/dl、eGFR≥25 ml/min per 1.73 m2且UACR 30–5000 mg/g的CKD患者,按1:1:1:1:1分为5组。

主要发现

  • 34周时UACR几何均值百分比变化:维立奴雷3 mg组16.7%(95%CI −0.6至37.1)、7.5 mg组15.0%(95%CI −1.85至34.6)、12 mg组14.0%(95%CI −3.4至34.4),别嘌醇组9.9%(95%CI −6.6至29.4),安慰剂组37.3%(95%CI 16.6至61.8),各组间无差异。
  • 60周时UACR和eGFR变化在各治疗组间无差异。
  • 维立奴雷联合别嘌醇较安慰剂剂量依赖性降低血清尿酸浓度。
  • 不良事件和严重不良事件比例在各治疗组间均衡。

临床怎么用

  • 不推荐使用维立奴雷联合别嘌醇以降低CKD患者白蛋白尿或延缓eGFR下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: The SAPPHIRE trial was designed to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with allopurinol in patients with CKD. Verinurad 3, 7.5, and 12 mg in combination with allopurinol 300 mg did not reduce albuminuria during 34 weeks treatment compared with allopurinol alone or placebo. Verinurad/allopurinol combination dose-dependently reduced serum urate concentrations compared with placebo. BACKGROUND: Hyperuricemia is associated with elevated risks of cardiovascular and chronic kidney disease (CKD). Since inhibition of urate transporter 1 has been suggested to be potentially nephroprotective, we performed a phase 2b study to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with the xanthine oxidase inhibitor allopurinol in patients with CKD and hyperuricemia. METHODS: In this randomized placebo and active controlled trial, we enrolled participants with serum urate concentrations ≥6.0 mg/dl, eGFR ≥25 ml/min per 1.73 m2, and a urinary albumin-creatinine ratio (UACR) 30–5000 mg/g to one of five treatment arms: placebo, placebo+allopurinol 300 mg/day, verinurad 3 mg+allopurinol 300 mg/day, verinurad 7.5 mg+allopurinol 300 mg/day, or verinurad 12 mg+allopurinol 300 mg/day in a 1:1:1:1:1 ratio. The primary end point was the change in UACR from baseline to 34 weeks. Secondary end points were changes from baseline in UACR at week 60 and changes in serum urate and eGFR at weeks 34 and 60. RESULTS: Between August 2019 and November 2021, 861 adults with CKD (mean age 65 years, 33.0% female, mean eGFR 48 ml/min per 1.73 m2, median UACR 217 mg/g) were enrolled. At 34 weeks, the geometric mean percentage change in UACR from baseline did not differ among treatment groups (16.7%, 95% confidence interval [CI], −0.6 to 37.1 in the 3 mg group, 15.0% [95% CI, −1.85 to 34.6] in the 7.5 mg group, 14.0% [95% CI, −3.4 to 34.4] in the 12 mg group versus 9.9% [95% CI, −6.6 to 29.4] in the allopurinol group, and 37.3% [95% CI, 16.6 to 61.8] in the placebo group). UACR and eGFR change from baseline did not differ among treatment groups after 60 weeks. Verinurad/allopurinol combination dose-dependently reduced serum urate concentrations compared with placebo. The proportion of patients with adverse events and serious adverse events was balanced among treatment groups. CONCLUSIONS: Verinurad in combination with allopurinol did not decrease UACR or eGFR decline, but further reduced serum urate compared with allopurinol alone or placebo. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: SAPPHIRE Trial registration number, NCT03990363.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Stack AG, Terkeltaub R, et al. Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial. J Am Soc Nephrol. 2024. PMID: 38564654. doi:10.1681/ASN.0000000000000326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。